大肠癌EGFR拮抗剂靶向治疗的进展与思考

分子靶向治疗为大肠癌的治疗提供了新的手段,它能够特异性地作用于肿瘤发生发展中起关键作用的靶分子及其调控的信号传导通路,从而达到治疗肿瘤的目的。在肿瘤分子靶向治疗的临床试验中,表皮生长因子受体（EGFR）拮抗剂对大肠癌的药物治疗已经显示出了潜在的疗效和良好的发展前景。本文拟就其理论基础及临床研究进展做一回顾。

The advance and questions of EGFR antagonists targeted therapy of colorectal cancer

New approaches targeting molecular abnormalities specific to colorectal cancer （CRC） have offered a new method to improve the therapeutic effect. The increasing knowledge in the molecular pathogenesis of CRC as well as the introduction of molecular targeted therapies in oncology has created an encouraging trend in the management of this malignancy. Early studies of targeted therapies for CRC, including targeting the EGFR pathway and inhibiting angiogenesis, have shown effective and great perspective. This reviewsummarizes the basic knowledge of those key aspects of the molecular pathogenesis. Relevant preclinical and clinical information on novel compounds for CRC are also reviewed.